Skip to main content

Table 3 Resolution of treatment-related side effects on follow-up (n = 14)

From: Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

typical side effects

CTC grade

end of treatment (N = 14)

6 weeks post completion of treatment, N = 14

4-5 months post completion of treatment, N = 14

mucositis

I

2 (14.3%)

5 (35.7%)

3 (21.4%)

 

II

8 (57.1%%)

2 (14.3%)

 
 

III

4 (28.6%)

0

 

dermatitis

I

2 (14.3%)

6 (42.9%)

 
 

II

6 (42.9%)

0

 
 

III

2 (14.3%)

0

 

acneiforme skin rash

I

5 (35.7%)

1 (7.1%)

 
 

II

9 (64.3%)

0

 
 

III

1 (7.1%)

0

 

dysphagia

I

5 (35.7%)

4 (28.6%)

 
 

II

7 (50%)

9 (64.3%)

3 (21.4%)

 

III

1 (7.1%)

1 (7.1%)

1 (7.1%)

xerostomia

I

8 (57.1%)

9 (64.3%)

10 (71.4%)

 

II

5 (35.7%)

2 (14.3%)

1 (7.1%)